Channel Therapeutics Programs
Pelthos Therapeutics outlines its Channel Therapeutics programs.

Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on cutaneous infectious diseases, with ZELSUVMI gel treating molluscum contagiosum.
pelthos.comCrawled Nov 6, 2026
Pelthos Therapeutics outlines its Channel Therapeutics programs.
Molluscum contagiosum is a contagious skin infection causing firm, itchy bumps, primarily in children under 14.
Explore NITRICILTM , a clinically proven technology that leverages nitric oxide’s naturally occurring antimicrobial and immunomodulary effects used to develop new therapies for unmet medical needs across multiple therapeutic areas.
The page tracks the progress of studies for treating various skin conditions.
XEGLYZE is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Commercially available in the first half of 2027.
XEPI is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older (1).
Pelthos Therapeutics publishes study findings in various publications.
Scott Plesha was named CEO of Pelthos Therapeutics, which launched its product Zelsuvmi in late 2024.
A proposed transaction will raise $50 million in equity capital for Pelthos Therapeutics, which is developing Zelsuvmi, the first FDA-approved at-home treatment for molluscum contagiosum.
Pelthos Therapeutics plans to launch Zelsuvmi for molluscum contagiosum in July 2025 and will trade on the NYSE American exchange under the ticker symbol “PTHS”.
Pelthos Therapeutics appointed five industry professionals to its Board of Directors.
Zelsuvmi, a prescription topical gel, is available for at-home use by patients, parents, and caregivers to treat molluscum contagiosum.
Pelthos Therapeutics reported strong physician response to Zelsuvmi, the first FDA-approved at-home treatment for molluscum contagiosum, and expanded its sales team.
Pelthos Therapeutics Board of Directors, Pelthos Board of Directors
Pelthos Therapeutics Leadership, Pelthos Leadership, Pelthos Executive Leadership Team
Pelthos Therapeutics develops solutions for people living with skin conditions.
Pelthos Therapeutics provides contact information for inquiries.
Pelthos Therapeutics commercializes innovative, safe, and effective treatments for patients with unmet medical needs.
Pelthos Therapeutics and Castle Creek Biosciences are merging to form a new biotechnology company specializing in serious skin diseases. The combination integrates Pelthos’s late-stage **D-Fi** franchise, targeting rare conditions including **Dystrophic Epidermolysis Bullosa (DEB)**, which holds **orphan drug designation**. The move consolidates expertise in developing treatments for severe dermatological disorders.
Pelthos Therapeutics secures expanded formulary coverage for its psoriasis treatment **ZELSUVMI® (berdazimer) Topical Gel, 10.3%** with a major Pharmacy Benefit Manager. The agreement extends access to an additional **24 million covered lives**, broadening patient eligibility under insurance plans. The move follows Pelthos’ earlier formulary additions and strengthens market distribution for the FDA-approved topical therapy.
Pelthos Therapeutics reports **Zelsuvmi® net product revenue** rising **45%** to **$15.4 million** in Q2 2026, up from **$10.7 million** in Q1 2026. The company’s flagship product shows strong sequential growth in sales. Financial results highlight continued commercial momentum for the therapy.
Pelthos Therapeutics schedules its **2026 Annual Meeting of Stockholders** for **September 29, 2026, at 9:00 a.m. ET**, held virtually. Eligible stockholders—those recorded by **August 4, 2026**—receive voting rights. The company plans to file the meeting notice and proxy statement in **early August 2026**.
Pelthos Therapeutics joins the **Russell 3000E™ Growth Benchmark**, **Russell Microcap®**, and **Russell Microcap® Growth** indexes as of June 29, 2026. The inclusion follows the annual Russell indexes reconstitution, expanding the biopharmaceutical company’s exposure in key market benchmarks. Pelthos develops therapeutic products targeting unmet medical needs, trading on the NYSE American under the ticker **PTHS**.
Pelthos Therapeutics reports **ZELSUVMI® net product revenue** rising **17% quarter-over-quarter**, from **$9.1 million** in Q4 2025 to **$10.7 million** in Q1 2026. The growth reflects continued demand for the company’s lead product. Pelthos does not disclose additional details on customer segments or geographic performance in this update.